Targeting Anaplastic Lymphoma Kinase in Oncology: Identification and Computational Validation of Novel Inhibitors for
Aftab Alam1, Mohammed H Alqarni1, Indrakant K Singh2
1Department of Pharmacognosy, College of Pharmacy, Prince Sattam Bin Abdulaziz University, Al-Kharj 11942, Saudi Arabia.
Background:
Anaplastic Lymphoma Kinase (ALK) is implicated in several cancers, including anaplastic large cell lymphoma, non-small cell lung cancer, and neuroblastoma. Targeted inhibition of ALK represents a promising therapeutic strategy.
Aims:
This study aimed to identify and evaluate potential ALK inhibitors using virtual screening and computational analyses to determine their binding stability, affinity, and dynamic behavior, ultimately assessing their potential as therapeutic agents for ALK-driven cancers.
Objective:
The objective of this study was to identify potential ALK inhibitors using virtual screening techniques and to evaluate their binding affinities and stability through computational analyses.
Methods:
This study utilized virtual screening to identify potential ALK inhibitors from the MTiOpen Screen Diverse library and selected three compounds (24331480, 26536128, and 24353407) based on their binding affinities. These compounds underwent optimization using Density Functional Theory (DFT) and were redocked to confirm binding stability. Molecular dynamics simulations, hydrogen bond analysis, MM/PBSA calculations, and PCA-based free energy landscape analysis were also carried out.
Results:
The re-docking experiments confirmed the stable and strong binding affinities of the selected compounds to the ALK active site. Molecular dynamics simulations revealed stable interactions throughout the 200 ns simulation period. Hydrogen bond analysis demonstrated consistent hydrogen bonds between key residues and the inhibitors. MM/PBSA calculations indicated favorable binding free energies, suggesting strong binding affinities. Finally, PCA-based free energy landscape analysis highlighted energetically favorable binding modes.
Conclusion:
The identified compounds (24331480, 26536128, and 24353407) exhibited promising inhibitory potential against ALK. These findings warrant further experimental validation to confirm their potential as therapeutic agents for ALK-driven cancers.
Insights
Computational screening identified three promising Anaplastic Lymphoma Kinase (ALK) inhibitors for cancer therapy. These compounds demonstrated stable binding and favorable interactions, warranting further investigation as potential ALK-targeted drugs.
Area of Science:
- Computational chemistry and drug discovery
- Oncology and molecular biology
Background:
- Anaplastic Lymphoma Kinase (ALK) is a key target in various cancers.
- Targeted ALK inhibition offers a promising therapeutic avenue.
Purpose of the Study:
- To identify and evaluate novel ALK inhibitors using virtual screening.
- To assess the binding stability, affinity, and dynamics of potential inhibitors.
Main Methods:
- Virtual screening of the MTiOpen Screen Diverse library.
- Compound selection (24331480, 26536128, 24353407) based on binding affinity.
- Density Functional Theory (DFT) optimization, re-docking, molecular dynamics simulations, MM/PBSA, and PCA analysis.
Main Results:
- Confirmed stable and strong binding of selected compounds to the ALK active site.
- Molecular dynamics simulations showed consistent interactions over 200 ns.
- Favorable binding free energies and energetically favorable binding modes were identified.
Conclusions:
- Identified compounds (24331480, 26536128, 24353407) show significant potential as ALK inhibitors.
- These findings support further experimental validation for ALK-driven cancer therapies.
More Related Videos
06:08Establishment and Characterization of Patient-Derived Xenograft Models of Anaplastic Thyroid Carcinoma and Head and Neck Squamous Cell Carcinoma
Published on: June 2, 2023
07:59Author Spotlight: Advancements in Molecular Biomarker Testing for Non-Squamous Non-Small Cell Lung Cancer
Published on: September 8, 2023
